DSpace Repository

Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial

Show simple item record

dc.contributor.author Anker, Stefan D.
dc.contributor.author Butler, Javed
dc.contributor.author Filippatos, Gerasimos
dc.contributor.author Khan, Muhammad Shahzeb
dc.contributor.author Ferreira, João Pedro
dc.contributor.author Bocchi, Edimar
dc.contributor.author Böhm, Michael
dc.contributor.author Brunner-La Rocca, Hans Pieter
dc.contributor.author Choi, Dong-Ju
dc.contributor.author Chopra, Vijay
dc.contributor.author Chuquiure-Valenzuela, Eduardo
dc.contributor.author Giannetti, Nadia
dc.contributor.author Gomez-Mesa, Juan Esteban
dc.contributor.author Janssens, Stefan
dc.contributor.author Januzzi, James L.
dc.contributor.author Gonzalez-Juanatey, Jose R.
dc.contributor.author Merkely, Bela
dc.contributor.author Nicholls, Stephen J.
dc.contributor.author Perrone, Sergio Víctor
dc.contributor.author Piña, Ileana L.
dc.contributor.author Ponikowski, Piotr
dc.contributor.author Senni, Michele
dc.contributor.author Seronde, Marie-France
dc.contributor.author Sim, David
dc.contributor.author Spinar, Jindrich
dc.contributor.author Squire, Iain
dc.contributor.author Taddei, Stefano
dc.contributor.author Tsutsui, Hiroyuki
dc.contributor.author Verma, Subodh
dc.contributor.author Vinereanu, Dragos
dc.contributor.author Zhang, Jian
dc.contributor.author Jamal, Waheed
dc.contributor.author Schnaidt, Sven
dc.contributor.author Schnee, Janet
dc.contributor.author Brueckmann, Martina
dc.contributor.author Pocock, Stuart J.
dc.contributor.author Zannad, Faiez
dc.contributor.author Packer, Milton
dc.contributor.author EMPEROR-Preserved Trial Committees and Investigators
dc.date.accessioned 2021-03-04T12:36:46Z
dc.date.available 2021-03-04T12:36:46Z
dc.date.issued 2020-12
dc.identifier.citation Anker SD, Butler J, Filippatos G, Shahzeb Khan M, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure -Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Seronde MF, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Preserved Trial Committees and Investigators. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. Eur J Heart Fail. 2020 Dec;22(12):2383-2392. doi: 10.1002/ejhf.2064. en_US
dc.identifier.uri http://localhost:8080/xmlui/handle/123456789/374
dc.identifier.uri https://doi.org/10.1002/ejhf.2064
dc.description.abstract Aims: EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares them with patients enrolled in prior HFpEF trials. Methods and results: EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, placebo-controlled trial in which 5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) >40%] with and without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to have elevated N-terminal pro B-type natriuretic peptide (NT-proBNP) concentrations (i.e. >300 pg/mL in patients without and >900 pg/mL in patients with atrial fibrillation) along with evidence of structural changes in the heart or documented history of heart failure hospitalization. Among patients enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North America), the mean age was 72 ± 9 years, 45% were women. Almost all patients had New York Heart Association class II or III symptoms (99.6%), and 23% had prior heart failure hospitalization within 12 months. Thirty-three percent of the patients had baseline LVEF of 41-50%. The mean LVEF (54 ± 9%) was slightly lower while the median NT-proBNP [974 (499-1731) pg/mL] was higher compared with previous HFpEF trials. Presence of comorbidities such as diabetes (49%) and chronic kidney disease (50%) were common. The majority of the patients were on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (80%) and beta-blockers (86%), and 37% of patients were on mineralocorticoid receptor antagonists. Conclusion: When compared with prior trials in HFpEF, the EMPEROR-Preserved cohort has a somewhat higher burden of comorbidities, lower LVEF, higher median NT-proBNP and greater use of mineralocorticoid receptor antagonists at baseline. Results of the EMPEROR-Preserved trial will be available in 2021. en_US
dc.language.iso eng en_US
dc.publisher Wiley en_US
dc.rights info:eu-repo/semantics/openAccess
dc.rights.uri https://creativecommons.org/licenses/by/2.5/ar/
dc.subject Heart Failure en_US
dc.subject Insuficiencia Cardíaca en_US
dc.title Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial en_US
dc.type info:eu-repo/semantics/publishedVersion
dc.type info:eu-repo/semantics/article en_US
dc.description.fil Fil: Perrone, Sergio Victor. Fleni. Departamento de Neurología. Servicio de Cardiología; Argentina.
dc.description.fil Fil: Anker, Stefan D. Berlin-Brandenburg Center for Regenerative Therapies. Department of Cardiology; Alemania. German Centre for Cardiovascular Research (DZHK); Alemania. Charité Universitätsmedizin Berlin; Alemania.
dc.description.fil Fil: Butler, Javed. University of Mississippi School of Medicine; Estados Unidos.
dc.description.fil Fil: Filippatos, Gerasimos. National and Kapodistrian University of Athens School of Medicine; Grecia.
dc.description.fil Fil: Khan, Muhammad Shahzeb. University of Mississippi School of Medicine; Estados Unidos.
dc.description.fil Fil: Ferreira, João Pedro. Université de Lorraine, Inserm INI-CRCT; Francia.
dc.description.fil Fil: Bocchi, Edimar. São Paulo University Medical School; Brasil.
dc.description.fil Fil: Böhm, Michael. Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes; Alemania.
dc.description.fil Fil: Brunner-La Rocca, Hans Pieter. Maastricht University Medical Center; Países Bajos.
dc.description.fil Fil: Choi, Dong-Ju. Seoul National University Bundang Hospital; Corea.
dc.description.fil Fil: Chopra, Vijay. Medanta Medicity to Max Superspeciality Hospital; India.
dc.description.fil Fil: Chuquiure, Eduardo. Instituto Nacional de Cardiología Ignacio Chavez; México.
dc.description.fil Fil: Giannetti, Nadia. Centre Universitaire de Sante McGill; Canadá.
dc.description.fil Fil: Gomez Mesa, Juan Esteban. Fundación Valle del Lili; Colombia.
dc.description.fil Fil: Janssens, Stefan. University Hospitals Leuven; Brasil.
dc.description.fil Fil: Januzzi, James L. Massachusetts General Hospital. Harvard Medical School; Estados Unidos.
dc.description.fil Fil: Gonzalez Juanatey, Jose R. Complejo Hospitalario Universitario de Santiago; España.
dc.description.fil Fil: Merkely, Bela. Semmelweis University; Hungría.
dc.description.fil Fil: Nicholls, Stephen J. Victorian Heart Institute, Monash University; Australia.
dc.description.fil Fil: Piña, Ileana L. Wayne State University; Estados Unidos.
dc.relation.ispartofVOLUME 22
dc.relation.ispartofNUMBER 12
dc.relation.ispartofPAGINATION 2383-2392
dc.relation.ispartofCOUNTRY Inglaterra
dc.relation.ispartofCITY Chichester
dc.relation.ispartofTITLE European journal of heart failure
dc.relation.ispartofISSN 1879-0844
dc.type.snrd info:ar-repo/semantics/artículo es_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/openAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess

Search DSpace


Browse

My Account

Statistics